Naim Alkhouri

2009–2026 年に発表

156
論文数
18,686
被引用数
75
h 指数
142
i10 指数

被引用数

Naim Alkhouri の年別被引用数1983 年: 被引用 1 件1997 年: 被引用 2 件1999 年: 被引用 1 件2009 年: 被引用 4 件2010 年: 被引用 13 件2011 年: 被引用 28 件2012 年: 被引用 58 件2013 年: 被引用 57 件2014 年: 被引用 71 件2015 年: 被引用 54 件2016 年: 被引用 85 件2017 年: 被引用 68 件2018 年: 被引用 70 件2019 年: 被引用 310 件2020 年: 被引用 643 件2021 年: 被引用 884 件2022 年: 被引用 968 件2023 年: 被引用 1,020 件2024 年: 被引用 2,154 件2025 年: 被引用 1,716 件2026 年: 被引用 103 件1984〜1996 年は被引用が無いため表示していません1998 年は被引用が無いため表示していません2000〜2008 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,039 件、この内訳の 21.1%中国: 引用元論文 1,229 件、この内訳の 12.7%イギリス: 引用元論文 576 件、この内訳の 6%イタリア: 引用元論文 530 件、この内訳の 5.5%ドイツ: 引用元論文 426 件、この内訳の 4.4%フランス: 引用元論文 337 件、この内訳の 3.5%スペイン: 引用元論文 309 件、この内訳の 3.2%日本: 引用元論文 259 件、この内訳の 2.7%韓国: 引用元論文 243 件、この内訳の 2.5%オーストラリア: 引用元論文 237 件、この内訳の 2.5%カナダ: 引用元論文 236 件、この内訳の 2.4%インド: 引用元論文 187 件、この内訳の 1.9%
0%21.1%その他 31.6%

分野

  • Medicine82.3%
  • Biochemistry, Genetics and Molecular Biology11.3%
  • Immunology and Microbiology1.8%
  • Engineering1.5%
  • Neuroscience0.7%
  • Nursing0.5%
  • その他1.9%

トピック

  • Liver Disease Diagnosis and Treatment24.2%
  • Liver Disease and Transplantation6.5%
  • Diet, Metabolism, and Disease6.5%
  • Liver Diseases and Immunity3.3%
  • Alcohol Consumption and Health Effects2.8%
  • Diabetes, Cardiovascular Risks, and Lipoproteins2.8%
  • その他53.9%

共著者

全論文

検索で開く
  1. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 1,701

  2. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 721

  3. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

    著者: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 442

  4. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

    著者: , , , , , , , - Nature Medicine 2023 被引用: 391

  5. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

    著者: , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 423

  6. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

    著者: , , , , , , , , , , , - The Lancet 2019 被引用: 765

  7. Challenges and opportunities in NASH drug development

    著者: , , , , - Nature Medicine 2023 被引用: 345

  8. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John Bate, Mark Danta, Jacob George, Alexander Hodge, Nickolas Kontorinis, S.A. Roberts, Santosh Sanagapalli, Richard Skoien, Alexander Thompson, Amany Zekry, Rudolf Stauber, Michael Trauner, Christophe Moreno, Hendrik Reynaert, Len Verbeke, Mário Reis Álvares‐da‐Silva, Edison Roberto Parise, Cláudia P. Oliveira, Roberta Chaves Araújo, Ana de Lourdes Candolo Martinelli, Meredith A. Borman, Natasha Chandok, Magdy Elkhashab, Hughie F. Fraser, Kelly Kaita, Mang Ma, Paul Marotta, Alnoor Ramji, Edward Tam, Eric M. Yoshida, Mark G. Swain, Giada Sebastiani, Denis Petrunia, Armand Abergel, Rodolphe Anty, Marc Bourlière, Jérôme Boursier, Christophe Bureau, Laurent Castéra, François Habersetzer, Christophe Hézode, V. de Lédinghen, Vincent Leroy, V. Loustaud‐Ratti, Philippe Mathurin, Stanislas Pol, Fabien Zoulim, Holger Hinrichsen, Patrick Ingiliz, Frank Lammert, Michael Manns, Jörn M. Schattenberg, Ingolf Schiefke, Christian Trautwein, Stefan Zeuzem, Aric J. Hui, K Li, Vincent Wai‐Sun Wong, Subrat Kumar Acharya, Abhijit Chowdhury, Ajay Duseja, Dharmesh Kapoor, Shrikant Mukewar, Shiv Kumar Sarin, Samir Shah, S. Shalimar, Ajit Sood, BV Tantry, Ziv Ben‐Ari, Helena Katchman ほか 540 名 - Journal of Hepatology 2020 被引用: 466

  9. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis

    著者: , , , , , , , , , , , , , , , - JAMA 2021 被引用: 344

  10. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

    著者: , , , , , , , , , , , , , , , - Journal of Hepatology 2022 被引用: 209

  11. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials

    著者: , , , , , , , , , - Journal of Hepatology 2020 被引用: 427

  12. Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

    著者: , , , , , , - Hepatology Communications 2021 被引用: 187

  13. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mitchell L. Shiffman, Simone I. Strasser, Vincent Wai‐Sun Wong, Naim Alkhouri, for the ATLAS Investigators - Hepatology 2020 被引用: 278

  14. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort

    著者: , , , , , , , , , , , , , , - Journal of Hepatology 2021 被引用: 286

  15. Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study

    著者: , , , , , , , , , , - Clinical Gastroenterology and Hepatology 2023 被引用: 148

  16. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nyingi Kemmer, Kris V. Kowdley, Michelle Lai, Eric Lawitz, Rohit Loomba, Mazen Noureddin, Angelo H. Paredes, Mary E. Rinella, Don C. Rockey, Miguel Rodriguez, Raymond A. Rubin, Michael Ryan, Arun J. Sanyal, Andrew Scanga, Thomas Sepe, Mitchell L. Shiffman, Mitchell L. Shiffman, Brent Tetri, Paul J. Thuluvath, Dawn M. Torres, John M. Vierling, Julia Wattacheril, Amanda Weiland, Donald L. Zogg - Gastroenterology 2019 被引用: 344

  17. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement

    著者: , , , , , , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2021 被引用: 272

  18. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances

    著者: , , , , , , , , , , , , - The American Journal of Gastroenterology 2018 被引用: 575

  19. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis

    著者: , , , , , , , , , - Journal of Hepatology 2021 被引用: 185

  20. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2022 被引用: 131

  21. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis

    著者: , , , , , , , , , , , , , , , , , , - Hepatology 2023 被引用: 82

  22. A global research priority agenda to advance public health responses to fatty liver disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shiv Kumar Sarin, Marcelo Silva, C Wendy Spearman, Emmanuel Tsochatzis, Luca Valenti, Marcela Villota‐Rivas, Shira Zelber‐Sagi, Jörn M. Schattenberg, Vincent Wai‐Sun Wong, Zobair M. Younossi, Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, Juan Pablo Arab, Patrizia Carrieri, Mazen Noureddin, William Alazawi, Naim Alkhouri, Saleh A. Alqahtani, Marco Arrese, Ramón Bataller, Thomas Berg, Paul Brennan, Patrizia Burra, Graciela Castro‐Narro, Helena Cortez‐Pinto, Kenneth Cusi, Nikos Dedes, Ajay Duseja, Sven Francque, Hannes Hagström, Terry T.‐K. Huang, Dana Ivancovsky‐Wajcman, Achim Kautz, Christopher J. Kopka, Aleksander Krag, Veronica Miller, Philip N. Newsome, Mary E. Rinella, Diana Romero, Shiv Kumar Sarin, Marcelo Silva, C. Wendy Spearman, Emmanuel Tsochatzis, Luca Valenti, Marcela Villota‐Rivas, Shira Zelber‐Sagi, Jörn M. Schattenberg, Vincent Wai‐Sun Wong, Zobair M. Younossi, Fredrik Åberg, Leon A. Adams, Khalid Al‐Naamani, Reda Albadawy, Zinaida Alexa, Michael Allison, Faisal Abdullatif Alnaser, Khalid Alswat, Mário Reis Álvares‐da‐Silva, Domenico Alvaro, Michele Alves‐Bezerra, Raúl J. Andrade, Quentin M. Anstee, Yaw Asante Awuku, Oidov Baatarkhuu, György Baffy, Shokhista Bakieva, Meena B. Bansal, Robert Barouki, Rachel L. Batterham ほか 241 名 - Journal of Hepatology 2023 被引用: 132

  23. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marcelo Silva, Mary E. Rinella, Ashwani K. Singal, Stuart C. Gordon, Michael Fuchs, Naim Alkhouri, Kenneth Cusi, Rohit Loomba, Jane Ranagan, Wayne Eskridge, Achim Kautz, Janus P. Ong, Marcelo Kugelmas, Yuichiro Eguchi, M. Diago, Ming‐Lung Yu, Lynn H. Gerber, Lisa Fornaresio, Fatema Nader, Linda Henry, Andrei Racila, Pegah Golabi, Maria Stepanova, Patrizia Carrieri, Jeffrey V. Lazarus - Journal of Hepatology 2023 被引用: 96

  24. Therapeutic pipeline in nonalcoholic steatohepatitis

    著者: , , , - Nature Reviews Gastroenterology & Hepatology 2021 被引用: 275